The world needs innovative antiviral drugs—but market incentives won’t align until it’s too late, Germany’s ‘head of challenges’ warns

SPRIND’s modeling shows that broad-spectrum antiviral drugs could reduce severe infections and deaths to less than 1% of what we saw with COVID-19. Read More